{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["metastatic unresectable colorectal cancer (mCRC) .","Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Metastatic Unresectable Colorectal Cancer (mcrc) ."],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2532981"],"location":["Belgium"],"study_start_month":["11"],"keyword":["VECTIBIX","AVASTIN","ELOXATIN","ADRUCIL"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"A trial comparing 2 chemotherapies with personalized treatment  with new drugs  in patients with colorectal cancer","description":"Primary objectives: - To assess Pogression Free Survival (PFS) of treatment\nPrimary endpoints: Progression-free survival (PFS) rate at 1 years after randomisation","dates":{"creation":"2014-11-15"},"accession":"2532981","cross_references":{"EU Clinical Trials Register":["2014-000543-33"]}}